お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:分子診断の世界市場 (~2026年):製品&サービス (試薬・キット・PoC&卓上機器)・用途 (COVID-19・肝炎・HAI・HIV・癌・遺伝子検査)・技術 (PCR・NGS・ISH)・エンドユーザー (病院・診断ラボ)・地域別
市場調査レポート
商品コード
999535

分子診断の世界市場 (~2026年):製品&サービス (試薬・キット・PoC&卓上機器)・用途 (COVID-19・肝炎・HAI・HIV・癌・遺伝子検査)・技術 (PCR・NGS・ISH)・エンドユーザー (病院・診断ラボ)・地域別

Molecular Diagnostics Market by Product & Service(Reagents, Kits, PoC & Tabletop Instruments), Application(COVID-19, Hepatitis, HAI, HIV, Oncology, Genetic Tests), Technology (PCR, NGS, ISH), End User (Hospitals, Diagnostic Labs)-Global Forecast to 2026

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 265 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.74円
分子診断の世界市場 (~2026年):製品&サービス (試薬・キット・PoC&卓上機器)・用途 (COVID-19・肝炎・HAI・HIV・癌・遺伝子検査)・技術 (PCR・NGS・ISH)・エンドユーザー (病院・診断ラボ)・地域別
出版日: 2021年04月07日
発行: MarketsandMarkets
ページ情報: 英文 265 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の分子診断の市場規模は予測期間中12.3%のCAGRで推移し、2021年の178億米ドルから、2026年には318億米ドルの規模に成長すると予測されています。

感染症や癌の有病率の増加、R&Dへの資金提供の増加、PoC検査機器の増加、技術の進歩などの要因が同市場の成長を推進しています。一方、償還シナリオが好ましくないことや、検査機器の高コスト性などの課題が市場のさらなる成長を一定程度抑制すると予測されています。

製品およびサービス別では、試薬・キットの部門が最大の成長を示すと予測されています。また、エンドユーザー別では、診断ラボの部門が最大のCAGRを示しています。感染症および癌の検査数の増加、効率的な診断・治療のためのヘルスケアインフラの強化などの要因が同部門の成長を牽引しています。

当レポートでは、世界の分子診断の市場を調査し、市場および製品の概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、技術・特許の動向、市場規模の推移・予測、製品&サービス区分・技術・用途・エンドユーザー・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
    • COVID-19:影響分析
  • 価格分析
  • 特許分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム分析
  • ポーターのファイブフォース分析
  • PESTLE分析
  • 規制状況
  • 貿易分析
  • 技術分析

第6章 市場分析・予測:製品・サービス別

  • 試薬・キット
  • 機器
    • 卓上機器
    • ポータブル&POC機器
  • サービス・ソフトウェア

第7章 市場分析・予測:技術別

  • ポリメラーゼ連鎖反応(PCR)
  • 等温核酸増幅技術(INAAT)
  • DNAシーケンシング・次世代シーケンシング
  • IN SITUハイブリダイゼーション(ISH)
  • DNAマイクロアレイ
  • その他

第8章 市場分析・予測:用途別

  • 感染症診断
    • COVID-19
    • 肝炎
    • CT / NG
    • HIV
    • HAI
    • HPV
    • 結核
    • インフルエンザ
    • その他
  • 癌検査
    • 乳癌
    • 結腸直腸癌
    • 肺癌
    • 前立腺癌
    • その他
  • 遺伝子検査
  • その他

第9章 市場分析・予測:エンドユーザー別

  • 診断ラボ
  • 病院・クリニック
  • その他

第10章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • イタリア
    • フランス
    • ロシア
    • スペイン
    • 英国
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第11章 競合情勢

  • 概要
  • 主要企業の戦略
  • 主要企業の収益シェア分析
  • 市場シェア分析
  • 競合リーダーシップマッピング
  • 主要企業の製品・地理的フットプリント分析
  • 競合シナリオ

第12章 企業プロファイル

  • 主要企業
    • F. HOFFMANN-LA ROCHE LTD.
    • HOLOGIC, INC.
    • BIOMERIEUX SA
    • ABBOTT LABORATORIES
    • QIAGEN
    • THERMO FISHER SCIENTIFIC INC.
    • ILLUMINA, INC.
    • MYRIAD GENETICS INC.
    • SIEMENS HEALTHINEERS AG
    • DANAHER CORPORATION
    • GRIFOLS S.A.
    • AGILENT TECHNOLOGIES INC.
    • BECTON, DICKINSON AND COMPANY
    • DIASORIN S.P.A
  • スタートアップ・SME企業
    • QUIDEL CORPORATION
    • GENETIC SIGNATURES
    • MDX HEALTH
    • EXACT SCIENCES
    • BIOCARTIS NV
    • TBG DIAGNOSTICS LTD.
    • GENMARK DIAGNOSTICS INC.
    • LUMINEX CORPORATION
    • HTG MOLECULAR DIAGNOSTICS
    • VELA DIAGNOSTICS
    • AMOY DIAGNOSTICS CO. LTD.
    • MOLBIO DIAGNOSTICS PVT. LTD.
    • ELITECHGROUP
    • SAVYON DIAGNOSTICS LTD.
    • ABACUS DIAGNOSTICA OY
    • GENEOMBIO TECHNOLOGIES PVT LTD.

第13章 付録

目次
Product Code: MD 2521

The global molecular diagnostics market size is projected to reach USD 31.8 billion by 2026 from USD 17.8 billion in 2021, at a CAGR of 12.3% during the forecast period. Market growth is driven by factors such as the increasing prevalence of infectious diseases and cancer, the rising funding for R&D, the increase in PoC testing devices and technological advancements. On the other hand, an unfavorable reimbursement scenario and the high cost of instruments is expected to limit market growth to a certain extent in the coming years.

"The reagents & kits accounted for the highest growth rate in the molecular diagnostics market, by product & service, during the forecast period"

The molecular diagnostics market is segmented into reagents & kits, instruments and other products. The reagents & kits segment accounted for the highest growth rate in the molecular diagnostics market in 2020. The requirement reagents & kits in large numbers compared to instruments is the main factor contributing to this segment's high growth rate. This segment's market growth can also be attributed to repeat purchases of reagents & kits compared to instruments.

"Infectious Disease Diagnostics segment accounted for the highest CAGR"

Based on the application, the molecular diagnostics market is segmented into infectious disease diagnostics, oncology testing, genetic tests and other applications. In 2020, the oncology testing segment accounted for the highest growth rate. Increasing incidence of cancer, technological advancements, and development of personalized medicine and companion diagnostic assays are the major factors driving this segment's growth.

"Diagnostic Laboratories segment accounted for the highest CAGR"

Based on end-users, the molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics and other end users. In 2020, the diagnostic laboratories segment accounted for the highest growth rate. This can be attributed to increased test volume of infectious diseases and cancer and strengthening healthcare infrastructure for efficient disease diagnosis and treatment.

"Asia Pacific: The fastest-growing region molecular diagnostics market"

The global molecular diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as the government efforts to increase awareness about the early detection of diseases and regular health check-ups; continuously rising healthcare expenditure; increasing number of hospitals and diagnostic laboratories in India and China; and strengthening research base for diagnostic procedures across India, China, and Japan are driving the growth of the molecular diagnostics market in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35%
  • By Designation: C-level - 30%, D-level - 20%, and Others - 50%
  • By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, Latin America - 9% , and the Middle East & Africa - 3%

Lits of Companies Profiled in the Report:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Hologic, Inc. (US)
  • bioMerieux SA (France)
  • Abbott Laboratories (US)
  • QIAGEN (Netherlands)
  • Thermo Fisher Scientific Inc. (US)
  • Illumina Inc. (US)
  • Siemens Healthineers AG (Germany)
  • Danaher Corporation (US)
  • Myriad Genetics Inc. (US)
  • Agilent Technologies Inc. (US)
  • Becton, Dickinson and Company (US)
  • DiaSorin S.p.A (Italy)
  • Grifols S.A. (Spain)
  • Quidel Corporation(US)
  • Genetic Signatures (Australia)
  • MDxHealth, Inc. (US)
  • Exact Sciences Corporation (US)
  • Biocartis NV (Belgium)
  • TBG Diagnostics Ltd. (Australia)
  • GenMark Diagnostics Inc. (US)
  • Luminex Corporation (US)
  • HTG Molecular Diagnostics Inc. (US)
  • Vela Diagnostics (Singapore)
  • Amoy Diagnostics Co., Ltd. (China)
  • Molbio Diagnostics Pvt. Ltd. (India)
  • ELITechGroup (France)
  • Savyon Diagnostics Ltd. (Israel)
  • ABACUS Diagnostica Oy (Finland)
  • geneOmbio Technologies Pvt. Ltd. (India)

Research Coverage:

This report provides a detailed picture of the global molecular diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall molecular diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • FIGURE 1 INCLUSIONS & EXCLUSIONS
    • 1.2.1 MARKETS COVERED
    • FIGURE 2 MOLECULAR DIAGNOSTICS MARKET
    • 1.2.2 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 3 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Key data from primary sources
      • 2.2.2.2 Key industry insights
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
    • FIGURE 5 MOLECULAR DIAGNOSTICS MARKET: BOTTOM-UP APPROACH
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 7 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 COVID-19 HEALTH ASSESSMENT
  • 2.7 COVID-19 ECONOMIC ASSESSMENT
  • 2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
    • FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
    • FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
  • 2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE MOLECULAR DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    • FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 15 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    • FIGURE 16 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 17 THE RISING ADOPTION OF POC DIAGNOSTICS IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
  • 4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 18 THE REAGENTS & KITS SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE MARKET, BY PRODUCT & SERVICE, IN 2021
  • 4.3 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    • FIGURE 19 THE PCR SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD
  • 4.4 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026
    • FIGURE 20 THE DIAGNOSTIC LABORATORIES SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE END USER MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 The increasing prevalence of infectious diseases and cancer
      • 5.2.1.2 Rising focus on R&D and funding in molecular diagnostics
      • 5.2.1.3 Increasing awareness for early disease diagnosis in developing countries
      • 5.2.1.4 Rising technological advancements in molecular diagnostics
      • 5.2.1.5 Increasing use of PoC diagnostic tests
    • 5.2.2 RESTRAINT
      • 5.2.2.1 Unfavorable reimbursement scenario
      • 5.2.2.2 The high cost of instruments
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 The growing significance of companion diagnostics
      • 5.2.3.2 Growth opportunities in emerging countries
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Changing regulatory landscape
      • 5.2.4.2 Operational barriers
      • 5.2.4.3 The introduction of alternative technologies
    • 5.2.5 COVID 19 IMPACT ANALYSIS
  • 5.3 PRICING ANALYSIS
    • TABLE 1 PRICING ANALYSIS OF MOLECULAR DIAGNOSTIC PRODUCTS (2021)
  • 5.4 PATENT ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 22 VALUE CHAIN ANALYSIS OF THE MOLECULAR DIAGNOSTICS MARKET
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 23 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • FIGURE 24 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT FROM NEW ENTRANTS
    • 5.8.2 THREAT FROM SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
  • 5.9 PESTLE ANALYSIS
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 NORTH AMERICA
      • 5.10.1.1 US
      • 5.10.1.2 Canada
    • 5.10.2 EUROPE
    • 5.10.3 ASIA PACIFIC
      • 5.10.3.1 China
      • 5.10.3.2 Japan
      • 5.10.3.3 India
    • 5.10.4 LATIN AMERICA
      • 5.10.4.1 Brazil
      • 5.10.4.2 Mexico
    • 5.10.5 MIDDLE EAST
    • 5.10.6 AFRICA
  • 5.11 TRADE ANALYSIS
    • 5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
      • 5.11.1.1 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (USD Million)
      • 5.11.1.2 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (Tons)
  • 5.12 TECHNOLOGY ANALYSIS

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
  • 6.2 REAGENTS & KITS
    • 6.2.1 THE RECURRENT PURCHASE OF REAGENTS & KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH
    • TABLE 3 REAGENTS & KITS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 6.3 INSTRUMENTS
    • TABLE 4 INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 5 INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • 6.3.1 TABLETOP INSTRUMENTS
      • 6.3.1.1 The outbreak of COVID-19 and rising incidences of cancer drives the growth of this segment
    • TABLE 6 TABLETOP INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • 6.3.2 PORTABLE & POC INSTRUMENTS
      • 6.3.2.1 The increasing adoption of PoC technologies drives the growth of this segment
    • TABLE 7 PORTABLE & POC INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 6.4 SERVICES & SOFTWARE
    • 6.4.1 THE GROWING UPTAKE OF ADVANCED INSTRUMENTS IN THE MOLECULAR DIAGNOSTICS MARKET DRIVES SEGMENT GROWTH
    • TABLE 8 SERVICES & SOFTWARE MARKET, BY REGION, 2019-2026 (USD MILLION)

7 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
  • 7.2 POLYMERASE CHAIN REACTION (PCR)
    • 7.2.1 THE GROWING USE OF PCR IN PROTEOMICS AND GENOMICS IS A MAJOR GROWTH DRIVER FOR THIS SEGMENT
    • TABLE 10 PCR TECHNOLOGY MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
    • 7.3.1 THE COST-BENEFITS OF THIS TECHNOLOGY IS A KEY FACTOR DRIVING THE MARKET GROWTH
    • TABLE 11 INAAT TECHNOLOGY MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
    • 7.4.1 INCREASING USE OF NGS IN THE DIAGNOSIS OF CANCER IS A GROWTH DRIVER FOR THIS SEGMENT
    • TABLE 12 DNA SEQUENCING & NGS TECHNOLOGY MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.5 IN SITU HYBRIDIZATION (ISH)
    • 7.5.1 THE RISING PREVALENCE OF CANCER AND GENETIC DISORDERS IS A KEY FACTOR DRIVING SEGMENT GROWTH
    • TABLE 13 ISH TECHNOLOGY MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.6 DNA MICROARRAY
    • 7.6.1 THE INTRODUCTION OF DNA MICROARRAY HAS ACCELERATED GENE EXPRESSION AND DISEASE DIAGNOSIS
    • TABLE 14 DNA MICROARRAY TECHNOLOGY MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.7 OTHER TECHNOLOGIES
    • TABLE 15 OTHER TECHNOLOGIES MARKET, BY REGION, 2019-2026 (USD MILLION)

8 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 16 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
  • 8.2 INFECTIOUS DISEASE DIAGNOSTICS
    • TABLE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 8.2.1 COVID-19
      • 8.2.1.1 The outbreak of the pandemic is a key factor driving market growth
    • TABLE 19 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 20 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • 8.2.2 HEPATITIS
      • 8.2.2.1 The global prevalence of hepatitis is a key factor driving market growth
    • TABLE 21 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 22 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION ASSAYS)
    • 8.2.3 CT/NG
      • 8.2.3.1 CT/NG infections are the most commonly prevalent STDs; key factor driving the market growth
    • TABLE 23 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 24 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • 8.2.4 HIV
      • 8.2.4.1 The increasing number of blood transfusions & donations will drive the market growth for this segment
    • TABLE 25 HIV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 26 HIV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • 8.2.5 HAI
      • 8.2.5.1 The rising burden of MRSA infections is a key factor driving the market growth for this segment
    • TABLE 27 HAI DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 28 HAI DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • 8.2.6 HPV
      • 8.2.6.1 Technological advancements such as rapid HPV diagnostics to drive the market growth for this segment
    • TABLE 29 HPV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 30 HPV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • 8.2.7 TUBERCULOSIS
      • 8.2.7.1 The increasing burden of TB globally to drive the market growth of this segment
    • TABLE 31 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 32 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • 8.2.8 INFLUENZA
      • 8.2.8.1 The rising focus on containing the spread of influenza drives the market growth for this segment
    • TABLE 33 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 34 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
    • 8.2.9 OTHER INFECTIOUS DISEASES
    • TABLE 35 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 8.3 ONCOLOGY TESTING
    • TABLE 36 ONCOLOGY TESTING MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 37 ONCOLOGY TESTING MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 8.3.1 BREAST CANCER
      • 8.3.1.1 The increasing prevalence of breast cancer is a key driver for market growth
    • TABLE 38 ONCOLOGY TESTING MARKET FOR BREAST CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 8.3.2 COLORECTAL CANCER
      • 8.3.2.1 The rising focus on the development of companion diagnostic assays drives the market growth
    • TABLE 39 ONCOLOGY TESTING MARKET FOR COLORECTAL CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 8.3.3 LUNG CANCER
      • 8.3.3.1 Increasing research for lung cancer biomarkers to drive the market growth
    • TABLE 40 ONCOLOGY TESTING MARKET FOR LUNG CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 8.3.4 PROSTATE CANCER
      • 8.3.4.1 Advancements in genomic technologies for the development of new biomarkers drive the market growth
    • TABLE 41 ONCOLOGY TESTING MARKET FOR PROSTATE CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 8.3.5 OTHER CANCERS
    • TABLE 42 OTHER CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 8.4 GENETIC TESTS
    • 8.4.1 GENETIC TESTING ENABLES THE DIAGNOSIS OF VARIOUS DISEASES
    • TABLE 43 GENETIC TESTS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 8.5 OTHER APPLICATIONS
    • TABLE 44 OTHER APPLICATIONS MARKET, BY REGION, 2019-2026 (USD MILLION)

9 MOLECULAR DIAGNOSTICS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 45 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 9.2 DIAGNOSTIC LABORATORIES
    • 9.2.1 INCREASING OUTSOURCING OF ACTIVITIES TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS DRIVES MARKET GROWTH
    • TABLE 46 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019-2026 (USD MILLION)
  • 9.3 HOSPITALS AND CLINICS
    • 9.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING MARKET GROWTH
    • TABLE 47 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2019-2026 (USD MILLION)
  • 9.4 OTHER END USERS
    • TABLE 48 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019-2026 (USD MILLION)

10 MOLECULAR DIAGNOSTICS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 49 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 25 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 50 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 51 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 52 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 53 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 54 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 The increasing prevalence of infectious diseases and cancer is a key factor expected to drive market growth in the US
    • TABLE 55 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 56 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 57 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 58 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 The availability of funding for genomics research in Canada drives the market growth
    • TABLE 59 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 60 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 61 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 62 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 63 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 64 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 65 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 66 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 67 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany
    • TABLE 68 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 69 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 70 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 71 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.2 ITALY
      • 10.3.2.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
    • TABLE 72 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 73 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 74 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 75 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Rising R&D expenditure in France to drive the market growth
    • TABLE 76 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 77 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 78 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 79 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.4 RUSSIA
      • 10.3.4.1 Increasing access to quality healthcare will support market growth in Russia
    • TABLE 80 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 81 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 82 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 83 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 The increasing demand for genetic testing is expected to drive market growth in Spain
    • TABLE 84 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 85 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 2019-2026 (USD MILLION)
    • TABLE 86 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 87 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.6 UK
      • 10.3.6.1 The increasing number of accredited diagnostic laboratories propels market growth for molecular diagnostics in the UK
    • TABLE 88 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 89 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 90 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 91 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 92 ROE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 93 ROE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 94 ROE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 95 ROE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 26 APAC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 96 APAC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 97 APAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 98 APAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 99 APAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 100 APAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
    • TABLE 101 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 102 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 103 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 104 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
    • TABLE 105 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 106 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 107 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 108 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Increasing private & public investments in the country's healthcare system will drive market growth
    • TABLE 109 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 110 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 111 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 112 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.4 AUSTRALIA
      • 10.4.4.1 The prevalence of infectious diseases in Australia is a key driver for market growth
    • TABLE 113 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 114 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 115 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 116 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC (ROAPAC)
    • TABLE 117 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 118 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 119 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 120 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 121 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 122 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 123 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 124 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 125 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.5.1 BRAZIL
      • 10.5.1.1 Improving healthcare infrastructure in Brazil to drive the growth of the molecular diagnostics market
    • TABLE 126 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 127 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 128 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 129 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.5.2 MEXICO
      • 10.5.2.1 The improving accessibility and affordability of healthcare services to drive market growth for molecular diagnostics
    • TABLE 130 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 131 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 132 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 133 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 134 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 135 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 136 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 137 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.6 MIDDLE EAST AND AFRICA
    • TABLE 138 MEA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 139 MEA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 140 MEA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 141 MEA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 28 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYERS (2020)
    • 11.4.1 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY TECHNOLOGY
      • 11.4.1.1 Polymerase Chain Reaction (PCR)
    • FIGURE 29 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
      • 11.4.1.2 DNA Sequencing and NGS
    • FIGURE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING AND NGS, MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
      • 11.4.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
    • TABLE 142 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY KEY PLAYERS, 2020
      • 11.4.1.4 In Situ Hybridization (ISH)
    • TABLE 143 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR ISH, BY KEY PLAYERS, 2020
    • 11.4.2 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY APPLICATION
      • 11.4.2.1 Infectious Disease Applications
    • TABLE 144 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET RANKING, BY KEY PLAYERS, 2020
  • 11.5 COMPETITIVE LEADERSHIP MAPPING
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 31 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
  • 11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SME (2020)
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 32 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SME, 2019
  • 11.7 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS
    • FIGURE 33 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET
  • 11.8 COMPETITIVE SCENARIO
    • FIGURE 34 MARKET EVALUATION MATRIX, 2018-2020
    • 11.8.1 MOLECULAR DIAGNOSTICS: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2018 - MARCH 2021)
    • TABLE 145 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
    • 11.8.2 MOLECULAR DIAGNOSTICS: DEALS (JANUARY 2018 - MARCH 2021)
    • TABLE 146 KEY DEALS
    • 11.8.3 MOLECULAR DIAGNOSTICS: OTHER DEVELOPMENTS (JANUARY 2018 - MARCH 2021)
    • TABLE 147 OTHER KEY DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business overview, Products offered, Recent developments, SWOT analysis, Right to Win)**
    • 12.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 148 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
    • FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
    • 12.1.2 HOLOGIC, INC.
    • TABLE 149 HOLOGIC, INC.: BUSINESS OVERVIEW
    • FIGURE 36 HOLOGIC, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.3 BIOMERIEUX SA
    • TABLE 150 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 37 BIOMERIEUX SA: COMPANY SNAPSHOT (2020)
    • 12.1.4 ABBOTT LABORATORIES
    • TABLE 151 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 38 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
    • 12.1.5 QIAGEN
    • TABLE 152 QIAGEN: BUSINESS OVERVIEW
    • FIGURE 39 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
    • 12.1.6 THERMO FISHER SCIENTIFIC INC.
    • TABLE 153 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
    • 12.1.7 ILLUMINA, INC.
    • TABLE 154 ILLUMINA, INC.: BUSINESS OVERVIEW
    • FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.8 MYRIAD GENETICS INC.
    • TABLE 155 MYRIAD GENETICS INC.: BUSINESS OVERVIEW
    • FIGURE 42 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2019)
    • 12.1.9 SIEMENS HEALTHINEERS AG
    • TABLE 156 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
    • FIGURE 43 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
    • 12.1.10 DANAHER CORPORATION
    • TABLE 157 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
    • 12.1.11 GRIFOLS S.A.
    • TABLE 158 GRIFOLS S.A.: BUSINESS OVERVIEW
    • FIGURE 45 GRIFOLS S.A: COMPANY SNAPSHOT (2020)
    • 12.1.12 AGILENT TECHNOLOGIES INC.
    • TABLE 159 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
    • FIGURE 46 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2020)
    • 12.1.13 BECTON, DICKINSON AND COMPANY
    • TABLE 160 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 47 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
    • 12.1.14 DIASORIN S.P.A
    • TABLE 161 DIASORIN S.P.A: BUSINESS OVERVIEW
    • FIGURE 48 DIASORIN S.P.A: COMPANY SNAPSHOT (2019)
  • 12.2 START UP/ SME PLAYERS
    • 12.2.1 QUIDEL CORPORATION
    • TABLE 162 QUIDEL CORPORATION: BUSINESS OVERVIEW
    • FIGURE 49 QUIDEL CORPORATION: COMPANY SNAPSHOT (2019)
    • 12.2.2 GENETIC SIGNATURES
    • TABLE 163 GENETIC SIGNATURES: BUSINESS OVERVIEW
    • FIGURE 50 GENETIC SIGNATURES: COMPANY SNAPSHOT (2020)
    • 12.2.3 MDX HEALTH
    • TABLE 164 MDX HEALTH: BUSINESS OVERVIEW
    • FIGURE 51 MDX HEALTH: COMPANY SNAPSHOT (2019)
    • 12.2.4 EXACT SCIENCES
    • TABLE 165 EXACT SCIENCES: BUSINESS OVERVIEW
    • FIGURE 52 EXACT SCIENCES: COMPANY SNAPSHOT (2019)
    • 12.2.5 BIOCARTIS NV
    • TABLE 166 BIOCARTIS NV: BUSINESS OVERVIEW
    • FIGURE 53 BIOCARTIS NV: COMPANY SNAPSHOT (2019)
    • 12.2.6 TBG DIAGNOSTICS LTD.
    • TABLE 167 TBG DIAGNOSTICS LTD.: BUSINESS OVERVIEW
    • FIGURE 54 TBG DIAGNOSTICS LTD.: COMPANY SNAPSHOT (2019)
    • 12.2.7 GENMARK DIAGNOSTICS INC.
    • TABLE 168 GENMARK DIAGNOSTICS INC.: BUSINESS OVERVIEW
    • FIGURE 55 GENMARK DIAGNOSTICS INC.: COMPANY SNAPSHOT (2019)
    • 12.2.8 LUMINEX CORPORATION
    • TABLE 169 LUMINEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 56 LUMINEX CORPORATION: COMPANY SNAPSHOT (2019)
    • 12.2.9 HTG MOLECULAR DIAGNOSTICS
    • TABLE 170 HTG MOLECULAR DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 57 HTG MOLECULAR DIAGNOSTICS: COMPANY SNAPSHOT (2019)
    • 12.2.10 VELA DIAGNOSTICS
    • TABLE 171 VELA DIAGNOSTICS: BUSINESS OVERVIEW
    • 12.2.11 AMOY DIAGNOSTICS CO. LTD.
    • TABLE 172 AMOY DIAGNOSTICS CO. LTD.: BUSINESS OVERVIEW
    • 12.2.12 MOLBIO DIAGNOSTICS PVT. LTD.
    • TABLE 173 MOLBIO DIAGNOSTICS PVT. LTD.: BUSINESS OVERVIEW
    • 12.2.13 ELITECHGROUP
    • TABLE 174 ELITECHGROUP: BUSINESS OVERVIEW
    • 12.2.14 SAVYON DIAGNOSTICS LTD.
    • TABLE 175 SAVYON DIAGNOSTICS LTD.: BUSINESS OVERVIEW
    • 12.2.15 ABACUS DIAGNOSTICA OY
    • TABLE 176 ABACUS DIAGNOSTICS OY: BUSINESS OVERVIEW
    • 12.2.16 GENEOMBIO TECHNOLOGIES PVT LTD.
    • TABLE 177 GENEOMBIO TECHNOLOGIES PVT. LTD.: BUSINESS OVERVIEW
  • *Business overview, Products offered, Recent developments, SWOT analysis, Right to Win might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 AVAILABLE CUSTOMIZATIONS
  • 13.5 RELATED REPORTS
  • 13.6 AUTHOR DETAILS
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.